Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 19, 2015, 56 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $59.05 to $2,925,000.00.

Highlighted Stocks Traded by Insiders:

American Equity Investment Life (AEL) - FREE Research Report

Grensteiner Ronald James, who is Vice President at American Equity Investment Life, sold 3,500 shares at $28.82 on March 19, 2015. Following this transaction, the Vice President owned 71,117 shares meaning that the stake was reduced by 4.69% with the 3,500-share transaction.

The shares most recently traded at $28.95, up $0.13, or 0.47% since the insider transaction. Historical insider transactions for American Equity Investment Life go as follows:

  • 4-Week # shares sold: 55,000
  • 12-Week # shares sold: 65,000
  • 24-Week # shares sold: 75,900

The average volume for American Equity Investment Life has been 396,200 shares per day over the past 30 days. American Equity Investment Life has a market cap of $2.2 billion and is part of the financial sector and insurance industry. Shares are down 1.95% year-to-date as of the close of trading on Thursday.

American Equity Investment Life Holding Company, through its subsidiaries, operates in the insurance business in 50 states and the District of Columbia. It underwrites fixed annuities, including fixed index annuities and fixed rate annuities, as well as single premium immediate annuities. The stock currently has a dividend yield of 0.69%. The company has a P/E ratio of 18.3. Currently, there is 1 analyst who rates American Equity Investment Life a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEL - FREE

TheStreet Quant Ratings rates American Equity Investment Life as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full American Equity Investment Life Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ANI Pharmaceuticals (ANIP) - FREE Research Report

Marken James G., who is Vice President, Operations at ANI Pharmaceuticals, sold 15,000 shares at $66.50 on March 19, 2015. Following this transaction, the Vice President, Operations owned 31,568 shares meaning that the stake was reduced by 32.21% with the 15,000-share transaction.

The shares most recently traded at $66.49, down $0.01, or 0.02% since the insider transaction. Historical insider transactions for ANI Pharmaceuticals go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 420,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 420,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 420,000

The average volume for ANI Pharmaceuticals has been 315,900 shares per day over the past 30 days. ANI Pharmaceuticals has a market cap of $716.5 million and is part of the health care sector and drugs industry. Shares are up 19.7% year-to-date as of the close of trading on Thursday.

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The company has a P/E ratio of 24.3. Currently, there are 2 analysts who rate ANI Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANIP - FREE

TheStreet Quant Ratings rates ANI Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full ANI Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salesforce.com (CRM) - FREE Research Report

Tomlinson Lawrence, who is Director at Salesforce.com, sold 400 shares at $68.30 on March 19, 2015. Following this transaction, the Director owned 26,391 shares meaning that the stake was reduced by 1.49% with the 400-share transaction.

The shares most recently traded at $68.83, up $0.53, or 0.77% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 228,427
  • 12-Week # shares sold: 667,527
  • 24-Week # shares sold: 1.5 million

The average volume for Salesforce.com has been 4.5 million shares per day over the past 30 days. Salesforce.com has a market cap of $44.6 billion and is part of the technology sector and computer software & services industry. Shares are up 16.14% year-to-date as of the close of trading on Thursday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 25 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null